Eli Lilly (NYSE: LLY) is the most valuable healthcare company in the world, worth more than $700 billion. Over the past 12 ...

Eli Lilly shares rose about 5% Tuesday morning after Goldman Sachs upgraded the pharmaceutical giant to Buy from Neutral, ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in ...

Cantor noted that Eli Lilly's (LLY) orforglipron, which is in Phase 3 testing, “has shown the strongest profile among oral GLP-1s.” Obesity data on GSBR-1290 is expected in Q2. The investment ...